Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

LNG Energy Group Corp. V.LNGE

Alternate Symbol(s):  V.LNGE.W | LNGNF

LNG Energy Group Corp is a Canada-based company, which is focused on the acquisition and development of natural gas production and exploration assets in Latin America. The Company’s assets include Sinu-San Jacinto-1(SSJN-1), Valle Inferior del Magdelana-41 (VIM-41), Valle Inferior del Magdalena-42 (VIM-42) and Sinu-San Jacinto 3-1(SSJN 3-1). The Company has a 50% working interest in SSJN-1, VIM-42 and SSJN 3-1. The Company has a 100% working interest in VIM-41. SSJN-1 covers approximately 226,000 acres. SSJN 3-1 covers approximately 83,000 acres. VIM-41 includes 93 billion cubic feet equivalent (BCFE) of net 3P reserves. It covers approximately 172,000 acres. VIM-42 includes 405 billion cubic feet (BCF) of prospective resource and covers approximately 228,000 acres.


TSXV:LNGE - Post by User

Post by Digger0144on Jun 20, 2021 3:54pm
237 Views
Post# 33418241

Revenue Generation...iSTRYM...Q1 2022

Revenue Generation...iSTRYM...Q1 2022Clinical Trials will take 2-3 years to complete and receive the necessary approvals from the governing entities.

However, ISTRYM will be the go to in the meantime.  It will start to play out in Q1 2022 and the market will begin to interpret the revenue generation model moving forward...this will dictate the value accordingly in terms of the share price...exciting...a new approach to supporting the mental health sector in terms of treatment, support and live monitoring through advanced technology...very nice indeed!

And so it begins!


 We’re moving forward with enthusiasm and remain on schedule to launch iSTRYM’s MVP to select clinics in Q3 of this year.”

Developing the distribution network of content and care protocols for psychedelic drugs allows MINDCURE to create value at all levels of the value chain: client, clinic, protocol developer, and drug developer. Currently in development, iSTRYM will be available to a select number of clinics throughout North America in Q3 2021. The software will be launched broadly and commercially to clinics in Q1 2022.



MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression | MINDCURE Health Inc.

<< Previous
Bullboard Posts
Next >>